BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

NCT02417129 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: Rituximab
DRUG: BI 695500

Sponsor

Boehringer Ingelheim